Activation of EAAT2 has been demonstrated as a useful therapeutic option to treat ALS, AD, PD, epilepsy, and stroke in preclinical studies, while several EAAT2 activating compounds have advanced through phase 2 clinical trials for ALS [44–51]. The gene discussed is SLC1A2; the disease is Parkinson disease.